GILEAD’S COMMITMENT: ELIMINATING HEPATITIS C BY 2030

The past is over with the last new infections globally every year.

The introduction of an affordable therapy in 2019 saves a billion dollars, reducing cases to almost zero.

The end of the hepatitis C epidemic by 2030 is possible if communities and partners work together. Gilead’s commitment to HCV

WHERE ARE WE NOW?

HCV elimination by 2030 is possible if communities and partners work together. Gilead’s commitment to HCV

INEQUALITIES IN HCV CARE

Many of these groups are at risk of: disease transmission, lack of access to effective treatments, and misinformation. An estimated 2.7 million people in the United States, 1.5 million people in Europe, and 6 million people in Asia are in these high-risk groups.

ELIMINATION CAN TRANSFORM LIVES

In our pursuit of the public health goal, we must also remember that each individual cure improves a life.

GILEAD’S COMMITMENT TO HCV

In 2019, Gilead launched HepConnect, a five-year, multi-million-dollar initiative to advance hepatitis C elimination in underserved communities in the United States.

Gilead is committed to support ambitious HCV elimination programs in a range of countries, including:

- Australia, Iceland, Switzerland, Italy, Mongolia, Spain, Egypt, France, Georgia, Japan, Netherlands, United Kingdom.
- The United States, Pakistan, Morocco, South Africa, Brazil, Colombia, Peru, Australia, New Zealand.
- Gilead is also committed to eliminating HCV globally in low-income, middle-income, and high-income countries and regions.

Gilead is also committed to eliminating HCV globally in low-income, middle-income, and high-income countries and regions. In addition, Gilead is committed to supporting HCV elimination programs in a range of countries, including:

- Gilead has taken a leadership position in a number of countries committed to microbial hepatitis C, including Egypt, which is investing in the elimination of HCV.

Through the LEGA-C PROGRAM, Gilead provides support to governments and community groups in low-income countries.

In 2019, 21 countries were selected for the LGH-C program, which provides support to governments and community groups in low-income countries.

Gilead has also taken a leadership position in an El Salvador, where the government and community groups are working together to eliminate HCV.

In 2019, Gilead provided support to the government of El Salvador, with the LGH-C program providing support to community groups in low-income countries.

Most people with hepatitis C are at risk of disease transmission, lack of access to effective treatments, and misinformation. An estimated 2.7 million people in the United States, 1.5 million people in Europe, and 6 million people in Asia are in these high-risk groups.

Gilead’s commitment to HCV

Gilead is committed to support ambitious HCV elimination programs in a range of countries, including:

- Australia, Iceland, Switzerland, Italy, Mongolia, Spain, Egypt, France, Georgia, Japan, Netherlands, United Kingdom.
- The United States, Pakistan, Morocco, South Africa, Brazil, Colombia, Peru, Australia, New Zealand.
- Gilead is also committed to eliminating HCV globally in low-income, middle-income, and high-income countries and regions.